Date:12/16/2009

-up data from over 1,800 people who had participated in the Age-Related Eye Disease Study evaluating the development of Age-Related Macular Degeneration ("AMD"). At the end of the 12-year period, information was graded to determine each individual's AMD status and comparisons were made with the intake of DHA, EPA, and the combination of DHA and EPA. Results showed that individuals who consumed the highest amounts of DHA alone or in combination with EPA had the lowest level of progression to AMD. EPA alone did not show a benefit.

In the Journal of Pediatric Gastroenterology and Nutrition (online October 2009), the ESPGHAN Committee on Nutrition updated their 1987 guidelines regarding the nutrient requirements of preterm infants. These new guidelines now include significant information regarding the importance of both DHA and ARA for the preterm infant. The Committee recommended that along with the other nutrients required for optimal development, DHA and ARA should be included in preterm infant formula to provide 11-27 mg/100 Kcal for DHA and 16-39 mg/100 Kcal for ARA. Any EPA present should not exceed 30 % of DHA supply. These recommended inclusion levels are equal to or greater than the inclusion levels generally found in preterm infant formulas currently marketed in the United States.

A study was published in Circulation (December 2009) in which, from 1984 to 1989, the serum fatty acids of 2,174 healthy men, age 42 to 60 years were measured. At the average follow-up period of 17.7 years, information regarding any previous diagnosis of atrial fibrillation ("AF"), a common cardiac arrhythmia, was compared to baseline fatty acid status. Results showed that DHA, and only DHA, and not EPA or ALA, was associated with a reduced risk for developing AF. Compared to the reference group, subjects in the highest DHA quartile had a 38% lower risk for developing AF.

Financial Guidance

Martek expe
'/>"/>

SOURCE Martek Biosciences Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Related biology technology :

1. Martek Signs Sole-Source Supply Agreement with Fonterra
2. Martek to Announce Fourth Quarter and Fiscal Year 2009 Results
3. Martek Announces Addition to Its Board of Directors
4. Martek to Present at Two Upcoming Investor Conferences
5. Martek Announces Settlement of Patent Dispute with Capsugel France
6. Federal Circuit Rules in Marteks Favor in Appeal of Patent Infringement Case
7. Martek Signs Sole-Source Supply Agreement with Milk Powder Solutions
8. Martek to Announce Third Quarter 2009 Results
9. Martek Signs Sole-Source ARA Supply Agreement with Puleva Food S.L.
10. BP and Martek Biosciences Enter Joint Development Agreement to Deliver Advanced Biodiesels
11. BP and Martek Biosciences Enter a Joint Development Agreement to Deliver Advanced Biodiesels